» Articles » PMID: 31864557

Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1

Overview
Journal J Thorac Oncol
Publisher Elsevier
Date 2019 Dec 23
PMID 31864557
Citations 3
Authors
Affiliations
Soon will be listed here.
Citing Articles

Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy.

Li G, Choi J, Kryczek I, Sun Y, Liao P, Li S Cancer Cell. 2023; 41(2):304-322.e7.

PMID: 36638784 PMC: 10286807. DOI: 10.1016/j.ccell.2022.12.008.


Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer.

Ding P, Wen L, Tong F, Zhang R, Huang Y, Dong X Cancer Drug Resist. 2022; 5(1):147-164.

PMID: 35582541 PMC: 8992596. DOI: 10.20517/cdr.2021.104.


A deficient MIF-CD74 signaling pathway may play an important role in immunotherapy-induced hyper-progressive disease.

Wang J, Hong J, Yang F, Liu F, Wang X, Shen Z Cell Biol Toxicol. 2021; 39(3):1169-1180.

PMID: 34797429 DOI: 10.1007/s10565-021-09672-3.